

Supporting Information

for

Mean Value Ensemble Hubbard-U Correction for

Spin-Crossover Molecules

Angel Albavera-Mata  ^{,†,‡} Richard G. Hennig  ^{,*,†,‡} and S.B. Trickey  ^{*,†,¶}

[†]*Center for Molecular Magnetic Quantum Materials, Quantum Theory Project, University of Florida, Gainesville, Florida 32611*

[‡]*Department of Materials Science and Engineering, University of Florida, 1885 Stadium Road, Gainesville, Florida 32611*

[¶]*Department of Physics and Department of Chemistry, University of Florida, P.O. Box 118435, Gainesville, Florida 32611*

E-mail: rhennig@ufl.edu; trickey@ufl.edu

Table S1: Element and valence electrons, Z_{val} , of the projector augmented wave potentials.

Element	Z_{val}	Potential
H	1	PAW_PBE H 15Jun2001
B	3	PAW_PBE B 06Sep2000
C	4	PAW_PBE C 08Apr2002
N	5	PAW_PBE N 08Apr2002
O	6	PAW_PBE O 08Apr2002
F	7	PAW_PBE F 08Apr2002
P	5	PAW_PBE P 06Sep2000
S	6	PAW_PBE S 06Sep2000
Cl	7	PAW_PBE Cl 06Sep2000
Cr	14	PAW_PBE Cr_sv 23Jul2007
Mn	15	PAW_PBE Mn_sv 23Jul2007
Fe	16	PAW_PBE Fe_sv 23Jul2007
Co	17	PAW_PBE Co_sv 23Jul2007
Ni	16	PAW_PBE Ni_pv 06Sep2000
Br	7	PAW_PBE Br 06Sep2000
I	7	PAW_PBE I 08Apr2002

Table S2: Calculated $U_{\text{eff}} = U - J$, in units of eV, from linear response on the low- (LS), high- (HS) and mean value ensemble spin (MS) states for PBE.

Complex	Ion	LS	HS	MS
[Cr(ddpd) ₂][BF ₄] ₂	Cr ^{II}	5.83	5.73	1.45
[Cr(Cp ^{iPr₄}) ₂]	Cr ^{II}	5.18	4.92	1.30
[Cr(I ₂)(depe) ₂]	Cr ^{II}	5.46	5.16	1.35
[Cr(Ind ^{Me-2}) ₂]	Cr ^{II}	5.19	5.11	1.30
[Mn(L ₁ tren)]	Mn ^{III}	5.03	4.82	1.28
[Mn(3,5-diBr-sal ₂ 323)][BF ₄]	Mn ^{III}	5.01	4.88	1.26
[Mn(L ₂)][PF ₆]	Mn ^{III}	5.02	4.88	1.27
[Mn(imSQ ^{OMe}) ₂ Cl]	Mn ^{III}	5.45	5.31	1.35
[Mn(Cp ^{1-Me}) ₂]	Mn ^{II}	4.41	3.96	1.12
[Mn(Cp ^{1-tBu}) ₂]	Mn ^{II}	4.41	3.58	1.13
[Mn(Cp ^{1,3-tBu}) ₂]	Mn ^{II}	4.54	3.90	1.14
[Mn(L-N ₃ O ₂) ₂ (CN) ₂ ·H ₂ O]	Mn ^{II}	5.33	6.43	1.42
[Fe(acac) ₂ (trien)][PF ₆]	Fe ^{III}	7.56	7.56	1.93
[Fe(qsal-Br) ₂][NO ₃]	Fe ^{III}	7.75	7.67	2.01
[Fe(3-OMe-salen) ₂][PF ₆]	Fe ^{III}	7.73	7.75	1.95
[Fe(qsal-5-OMe) ₂][BF ₄]	Fe ^{III}	7.71	7.89	1.98
[Fe(phen) ₂ (NCS) ₂]	Fe ^{II}	7.88	8.21	2.03
[Fe(stpy) ₂ (NCS) ₂]	Fe ^{II}	7.98	8.47	2.06
[Fe(bpp) ₃][BF ₄] ₂	Fe ^{II}	7.52	7.64	1.92
[Fe(H ₂ B(pz) ₂) ₂ (bipy)]	Fe ^{II}	7.82	8.28	2.02
[Fe(tzpy) ₂ (NCS) ₂]	Fe ^{II}	7.87	8.32	2.04
[Fe(tBu ₂ qsal) ₂]	Fe ^{II}	8.08	8.01	2.04
[Fe(L ₃) ₃][ClO ₄] ₂	Fe ^{II}	7.77	7.69	1.96
[Co(NAd)(Tp ^{tBu,Me})]	Co ^{III}	6.82	6.42	1.63
[Co(^{Ar} L)(NtBu)]	Co ^{III}	6.54	6.18	1.57
[Co(terpy) ₂]	Co ^{II}	6.60	6.54	1.66
[Co(H ₂ (fsa) ₂ en)(Py) ₂]	Co ^{II}	6.49	6.27	1.59
[Co(terpyridone) ₂][ClO ₄] ₂	Co ^{II}	6.61	6.28	1.62
[Co(papl) ₂]	Co ^{II}	6.60	6.82	1.66
[Co(MeO-terpy) ₂][BF ₄] ₂	Co ^{II}	6.60	6.25	1.60
[Co(PM-BiA) ₂][NCS] ₂	Co ^{II}	6.56	7.01	1.74
[Ni(α -phpyNO) ₂ Br ₂]	Ni ^{II}	7.15	6.44	1.64
[Ni(phpyNO) ₂ Cl ₂]	Ni ^{II}	6.84	6.41	1.67
[Ni(β -phpyNO) ₂ Br ₂]	Ni ^{II}	6.96	6.31	1.67

ddpd = N,N'-dimethyl-N,N'-dipyridine-2-yl-pyridine-2,6-diamine, Cp^{iPr₄} = tetraisopropylcyclopentadienide, depe = 1,2-bis(diethylphosphino)ethane, Ind^{Me-2} = bis(2-methylindenyl), L₁tren = tris(2-(pyrrol-2-yl)methyleneamino)ethylamine, 3,5-diBr-sal₂323 = 2,2'-(2,6,9,13-tetraazatetradeca-1,13-diene-1,14-diyl)bis(4,6-dibromophenolato), L₂ = (2,2'-(2,6,9,13-tetraazatetradeca-1,13-diene-1,14-diyl)diphenol), imSQ^{OMe} = 4,6-di-*tert*-butyl-N-(2-methoxyphenyl)-o-aminophenol, Cp^{1-Me} = methylcyclopentadiene, Cp^{1-tBu} = *tert*-butylcyclopentadienyl, Cp^{1,3-tBu} = *tert*-butylcyclopenta-1,3-diene, L-N₃O₂ = 2,13-dimethyl-6,9-dioxa-3,12,18-triaza[12.3.1]-octadeca-1(18),12,14,16-pentaene, acac = acetylacetone, trien = triethylenetetramine, qsal-Br = (N-8-quino-lyl)-5-Br-salicylaldehyde, 3-OMe-salen = (2-(((2-(ethylamino)ethyl)imino)methyl)-6-methoxyphenolato-N,N',O), qsal-5-OMe = N-(8-quino-lyl)salicylaldehyde, phen = phenanthroline, stpy = 4-styrylpyridine, bpp = (2,6-di(pyrazol-1-yl)pyridine), H₂B(pz)₂ = dihydrogen bis(pyrazol-1-yl)borate, bipy = bipyridine, tzpy = (3-(2-pyridyl)(1,2,3)triazolo(1,5-a)pyridine), tBu₂qsal = 2,4-di(*tert*-butyl)-6-((quinoline-8-ylimino)methyl)phenol, L₃ = 1-acetic ethyl-2-(pyridine-2-yl)-imidazole, Ad = 1-adamantyl, Tp^{tBu,Me} = hydrotris(3-*tert*-butyl,5-methyl-pyrazol-1-yl)borate, ^{Ar}L = 5-mesityl-1,9-(2,4,6-triphenylphenyl)dipyririn, terpy = terpyridine, H₂(fsa)₂en = 3-formylsalicylic acid-ethylenediamine, papl = 1-(2-pyridylazo)-2-phenanthrol, MeO-terpy = 4'-methoxy-2,2',6',2''-terpyridine, PM-BiA = *cis*-bis(thiocyanato)bis(N-(2-pyridylmethylene)aminobiphenyl), α -phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide phase α , phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide, β -phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide phase β .

Table S3: Differences in HOMO-LUMO gap, $\Delta\epsilon_{\text{gap}}$, in units of eV, between results calculated with PBE+ U_{eff} and results with PBE, $[\Delta\epsilon_{\text{gap}}(\text{PBE}+U_{\text{eff}})] - [\Delta\epsilon_{\text{gap}}(\text{PBE})]$, for the low-spin (LS) and high-spin (HS) states.

Complex	Ion	LS	HS
[Cr(ddpd) ₂][BF ₄] ₂	Cr ^{II}	0.09	0.34
[Cr(Cp ^{iPr₄}) ₂]	Cr ^{II}	0.35	0.35
[Cr(I ₂)(depe) ₂]	Cr ^{II}	0.32	0.53
[Cr(Ind ^{Me-2}) ₂]	Cr ^{II}	0.13	0.51
[Mn(L ₁ tren)]	Mn ^{III}	0.51	0.54
[Mn(3,5-diBr-sal ₂ 323)][BF ₄]	Mn ^{III}	0.52	0.21
[Mn(L ₂)][PF ₆]	Mn ^{III}	0.45	0.17
[Mn(imSQ ^{OMe}) ₂ Cl]	Mn ^{III}	-0.11	0.10
[Mn(Cp ^{1-Me}) ₂]	Mn ^{II}	0.61	0.50
[Mn(Cp ^{1-tBu}) ₂]	Mn ^{II}	0.60	0.50
[Mn(Cp ^{1,3-tBu}) ₂]	Mn ^{II}	0.61	0.51
[Mn(L-N ₃ O ₂) ₂ (CN) ₂ ·H ₂ O]	Mn ^{II}	0.22	0.18
[Fe(acac) ₂ (trien)][PF ₆]	Fe ^{III}	0.88	0.70
[Fe(qsal-Br) ₂][NO ₃]	Fe ^{III}	0.41	0.22
[Fe(3-OMe-salen) ₂][PF ₆]	Fe ^{III}	0.65	0.30
[Fe(qsal-5-OMe) ₂][BF ₄]	Fe ^{III}	0.41	0.22
[Fe(phen) ₂ (NCS) ₂]	Fe ^{II}	-0.02	0.01
[Fe(stpy) ₂ (NCS) ₂]	Fe ^{II}	0.08	0.23
[Fe(bpp) ₃][BF ₄] ₂	Fe ^{II}	0.22	-0.11
[Fe(H ₂ B(pz) ₂) ₂ (bipy)]	Fe ^{II}	0.28	0.37
[Fe(tzpy) ₂ (NCS) ₂]	Fe ^{II}	0.08	0.14
[Fe(tBu ₂ qsal) ₂]	Fe ^{II}	0.12	0.12
[Fe(L ₃) ₃][ClO ₄] ₂	Fe ^{II}	0.30	0.71
[Co(NAd)(Tp ^{tBu,Me})]	Co ^{III}	0.03	0.31
[Co(^{Ar} L)(NtBu)]	Co ^{III}	0.58	0.61
[Co(terpy) ₂]	Co ^{II}	-0.03	-0.01
[Co(H ₂ (fsa) ₂ en)(Py) ₂]	Co ^{II}	0.37	0.76
[Co(terpyridone) ₂][ClO ₄] ₂	Co ^{II}	-0.32	0.19
[Co(papl) ₂]	Co ^{II}	-0.01	0.23
[Co(MeO-terpy) ₂][BF ₄] ₂	Co ^{II}	0.08	0.47
[Co(PM-BiA) ₂][NCS] ₂	Co ^{II}	-0.01	0.04
[Ni(α -phpyNO) ₂ Br ₂]	Ni ^{II}	-0.14	0.10
[Ni(phpyNO) ₂ Cl ₂]	Ni ^{II}	0.00	0.15
[Ni(β -phpyNO) ₂ Br ₂]	Ni ^{II}	-0.27	0.10

ddpd = N,N'-dimethyl-N,N'-dipyridine-2-yl-pyridine-2,6-diamine, Cp^{iPr₄} = tetraisopropylcyclopentadienide, depe = 1,2-bis(diethylphosphino)ethane, Ind^{Me-2} = bis(2-methylindenyl), L₁tren = tris(2-((pyrrol-2-yl)methyleneamino)ethyl)amine, 3,5-diBr-sal₂323 = 2,2'-(2,6,9,13-tetraazatetradeca-1,13-diene-1,14-diyl)bis(4,6-dibromophenolato), L₂ = (2,2'-(2,6,9,13-tetraazatetradeca-1,13-diene-1,14-diyl)diphenol), imSQ^{OMe} = 4,6-di-*tert*-butyl-N-(2-methoxyphenyl)-o-aminophenol, Cp^{1-Me} = methylcyclopentadiene, Cp^{1-tBu} = *tert*-butylcyclopentadienyl, Cp^{1,3-tBu} = *tert*-butylcyclopenta-1,3-diene, L-N₃O₂ = 2,13-dimethyl-6,9-dioxa-3,12,18-triazabicyclo[12.3.1]octadeca-1(18),2,12,14,16-pentaene, acac = acetylacetone, trien = triethylenetetramine, qsal-Br = (N-8-quino-lyl)-5-Br-salicylaldiminate, 3-OMe-salen = (2-((2-(ethylamino)ethyl)imino)methyl)-6-methoxyphenolato-N,N',O), qsal-5-OMe = N-(8-quino-lyl)salicylaldiminate, phen = phenanthroline, stpy = 4-styrylpypyridine, bpp = (2,6-di(pyrazol-1-yl)pyridine), H₂B(pz)₂ = dihydrogen bis(pyrazol-1-yl)borate, bipy = bipyridine, tzpy = (3-(2-pyridyl)(1,2,3)triazolo(1,5-a)pyridine), tBu₂qsal = 2,4-di(*tert*-butyl)-6-((quinoline-8-ylimino)methyl)phenol, L₃ = 1-acetic ethyl-2-(pyridine-2-yl)-imidazole, Ad = 1-adamantyl, Tp^{tBu,Me} = hydrotris(3-*tert*-butyl,5-methyl-pyrazol-1-yl)borate, ^{Ar}L = 5-mesityl-1,9-(2,4,6-triphenylphenyl)dipyrrin, terpy = terpyridine, H₂(fsa)₂en = 3-formylsalicylic acid-ethylenediamine, papl = 1-(2-pyridylazo)-2-phenanthrol, MeO-terpy = 4'-methoxy-2,2':6',2''-terpyridine, PM-BiA = *cis*-bis(thiocyanato)bis(N-(2-pyridylmethylene)aminobiphenyl), α -phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide phase α , phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide, β -phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide phase β .

Table S4: Spin-crossover energies, ΔE_{HL} , in units of eV, calculated with the PBE and PBE+ U_{eff} density functional approximations.

Complex	Ion	PBE	PBE+ U_{eff}		
			LS	HS	MS
[Cr(ddpd) ₂][BF ₄] ₂	Cr ^{II}	0.46	-0.59	-0.58	0.25
[Cr(Cp ^{iPr₄}) ₂]	Cr ^{II}	0.68	-0.68	-0.61	0.34
[Cr(I ₂)(depe) ₂]	Cr ^{II}	0.44	-0.70	-0.65	0.12
[Cr(Ind ^{Me-2}) ₂]	Cr ^{II}	0.16	-0.89	-0.87	-0.11
[Mn(L ₁ tren)]	Mn ^{III}	0.50	-0.51	-0.47	0.20
[Mn(3,5-diBr-sal ₂ 323)][BF ₄]	Mn ^{III}	0.50	-0.53	-0.51	0.20
[Mn(L ₂)][PF ₆]	Mn ^{III}	0.53	-0.49	-0.47	0.25
[Mn(imSQ ^{OMe}) ₂ Cl]	Mn ^{III}	0.55	0.26	0.26	0.43
[Mn(Cp ^{1-Me}) ₂]	Mn ^{II}	1.15	-0.91	-0.70	0.64
[Mn(Cp ^{1-tBu}) ₂]	Mn ^{II}	1.09	-0.96	-0.58	0.58
[Mn(Cp ^{1,3-tBu}) ₂]	Mn ^{II}	1.09	-1.03	-0.74	0.56
[Mn(L-N ₃ O ₂) ₂ (CN) ₂ ·H ₂ O]	Mn ^{II}	1.06	-1.41	-1.78	0.41
[Fe(acac) ₂ (trien)][PF ₆]	Fe ^{III}	0.48	-1.17	-1.17	0.06
[Fe(qsal-Br) ₂][NO ₃]	Fe ^{III}	1.03	-1.20	-1.14	0.39
[Fe(3-OMe-salen) ₂][PF ₆]	Fe ^{III}	0.99	-1.14	-1.14	0.37
[Fe(qsal-5-OMe) ₂][BF ₄]	Fe ^{III}	0.95	-1.20	-1.24	0.32
[Fe(phen) ₂ (NCS) ₂]	Fe ^{II}	0.89	-1.38	-1.41	0.14
[Fe(stpy) ₂ (NCS) ₂]	Fe ^{II}	0.83	-1.38	-1.43	0.05
[Fe(bpp) ₃][BF ₄] ₂	Fe ^{II}	1.15	-1.27	-1.31	0.38
[Fe(H ₂ B(pz) ₂) ₂ (bipy)]	Fe ^{II}	0.70	-1.26	-1.31	0.24
[Fe(tzpy) ₂ (NCS) ₂]	Fe ^{II}	0.95	-1.40	-1.45	0.21
[Fe(tBu ₂ qsal) ₂]	Fe ^{II}	0.90	-1.40	-1.39	0.14
[Fe(L ₃) ₃][ClO ₄] ₂	Fe ^{II}	1.36	-1.17	-1.15	0.56
[Co(NAd)(Tp ^{tBu,Me})]	Co ^{III}	0.27	-0.91	-0.57	-0.02
[Co(^{Ar} L)(NtBu)]	Co ^{III}	0.50	-0.48	-0.44	0.21
[Co(terpy) ₂]	Co ^{II}	-0.03	-0.02	-0.02	-0.03
[Co(H ₂ (fsa) ₂ en)(Py) ₂]	Co ^{II}	0.53	-0.63	-0.60	0.22
[Co(terpyridone) ₂][ClO ₄] ₂	Co ^{II}	0.70	-0.65	-0.61	0.31
[Co(papl) ₂]	Co ^{II}	1.00	-1.10	-1.18	0.86
[Co(MeO-terpy) ₂][BF ₄] ₂	Co ^{II}	0.76	-0.61	-0.57	0.36
[Co(PM-BiA) ₂][NCS] ₂	Co ^{II}	0.38	-1.57	-1.71	-0.10
[Ni(α -phpyNO) ₂ Br ₂]	Ni ^{II}	0.25	-0.60	-0.58	0.05
[Ni(phpyNO) ₂ Cl ₂]	Ni ^{II}	0.27	-0.59	-0.60	-0.04
[Ni(β -phpyNO) ₂ Br ₂]	Ni ^{II}	0.15	0.04	0.04	0.06

ddpd = N,N'-dimethyl-N,N'-dipyridine-2-yl-pyridine-2,6-diamine, Cp^{iPr₄} = tetraisopropylcyclopentadienide, depe = 1,2-bis(diethylphosphino)ethane, Ind^{Me-2} = bis(2-methylindenyl), L₁tren = tris(2-((pyrrol-2-yl)methyleneamino)ethyl)amine, 3,5-diBr-sal₂323 = 2,2'-(2,6,9,13-tetraazatetradeca-1,13-diene-1,14-diy)bis(4,6-dibromophenolato), L₂ = (2,2'-(2,6,9,13-tetraazatetradeca-1,13-diene-1,14-diy)diphenol), imSQ^{OMe} = 4,6-di-*tert*-butyl-N-(2-methoxyphenyl)-o-aminophenol, Cp^{1-Me} = methylcyclopentadiene, Cp^{1-tBu} = *tert*-butylcyclopentadienyl, Cp^{1,3-tBu} = *tert*-butylcyclopenta-1,3-diene, L-N₃O₂ = 2,13-dimethyl-6,9-dioxa-3,12,18-triazabicyclo[12.3.1]-octadeca-1(18),2,12,14,16-pentaene, acac = acetylacetone, trien = triethylenetetramine, qsal-Br = (N-8-quino-lyl)-5-Br-salicylaldehyde, 3-OMe-salen = (2-((2-(ethylamino)ethyl)imino)methyl)-6-methoxyphenolato-N,N',O), qsal-5-OMe = N-(8-quino-lyl)salicylaldehyde, phen = phenanthroline, stpy = 4-styrylpyridine, bpp = (2,6-di(pyrazol-1-yl)pyridine), H₂B(pz)₂ = dihydrogen bis(pyrazol-1-yl)borate, bipy = bipyridine, tzpy = (3-(2-pyridyl)(1,2,3)triazolo(1,5-a)pyridine), tBu₂qsal = 2,4-di(*tert*-butyl)-6-((quinoline-8-ylimino)methyl)phenol, L₃ = 1-acetic ethyl-2-(pyridine-2-yl)-imidazole, Ad = 1-adamantyl, Tp^{tBu,Me} = hydrotris(3-*tert*-butyl,5-methyl-pyrazol-1-yl)borate, ^{Ar}L = 5-mesityl-1,9-(2,4,6-triphenylphenyl)dipyrroline, terpy = terpyridine, H₂(fsa)₂en = 3-formylsalicylic acid-ethylenediamine, papl = 1-(2-pyridylazo)-2-phenanthrol, MeO-terpy = 4'-methoxy-2',6',2''-terpyridine, PM-BiA = *cis*-bis(thiocyanato)bis(N-(2-pyridylmethylene)aminobiphenyl), α -phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide phase α , phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide, β -phpyNO = *tert*-butyl 5-phenyl-2-pyridyl nitroxide phase β .